GlassScriptPhysician profile
Mark L Gillett
NPI 1497742886
$9,518.16
in general payments reported to CMS, 2019-2025
50 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $1,366 · 2021: $2,313 · 2022: $1,965 · 2023: $1,283 · 2024: $744 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,377.89 | 2019-2024 | |
| Pfizer INC. | $1,177.82 | 2019-2025 | |
| Lilly USA, LLC | $1,079.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $975.88 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $730.60 | 2019-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $584.28 | 2019-2025 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $459.56 | 2019-2024 | Belsomra, Steglatro, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.89 | 2019-2024 | Jardiance |
| Antares Pharma, INC. | $313.51 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Amarin Pharma, INC. | $310.15 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.99 | 2020-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $203.62 | 2022 | |
| Glaxosmithkline, LLC. | $187.44 | 2020-2024 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $126.38 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $120.34 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gillett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.